Dermatology · PsoriasisRegulatory Approvalregulatorymid-term

FDA Submission Status Update for Calcipotriene by Glenmark

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/28/2026, 12:31:54 AM

Assessment confidence: 58% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The acceptance of Glenmark's ANDA submission for Calcipotriene is a significant regulatory milestone that could enhance their competitive position in the psoriasis market. Monitoring the approval timeline is crucial for anticipating market dynamics and potential shifts in competitive landscape. Regulatory context from FDA (FDA AP — CALCIPOTRIENE (SUPPL)) supports the near-term read. Assessment grounded in 21 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should monitor the approval timeline and prepare for potential market entry strategies. The strongest clinical anchor is Korean Post-marketing Surveillance for Xeljanz XR (ClinicalTrials.gov), sponsor/company relevance (pfizer). In Dermatology · Psoriasis, 6 regulatory and 3 competitive items passed relevance filtering for Glenmark.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals. This submission may enhance Glenmark's position in the psoriasis treatment market, potentially impacting competitors with similar products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — CALCIPOTRIENE (SUPPL) (FDA). Entity match (glenmark); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The acceptance of the ANDA indicates progress in the regulatory process, but the final approval decision remains pending, which could affect Glenmark's market strategy.

Key Risks

Elevated medium regulatory exposure for Glenmark could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Korean Post-marketing Surveillance for Xeljanz XR) could weigh on Glenmark through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Successful approval and market entry could allow Glenmark to capture market share from existing psoriasis treatments, impacting revenue streams for competitors.
Portfolio teams should monitor the approval timeline and prepare for potential market entry strategies.

What Would Change This Assessment

This becomes more urgent if Key milestones include the final approval decision and any subsequent market launch announcements.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — CALCIPOTRIENE (SUPPL)
FDAhigh relevance
Entity match (glenmark); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — NINTEDANIB ESYLATE (ORIG)
FDAhigh relevance
Entity match (glenmark); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — RYALTRIS (SUPPL)
FDAhigh relevance
Entity match (glenmark); Regulatory pathway relevance (nda)
FDA document
View source
FDA’s Drug Registration and Listing Workshop: Compliance, Regulatory and Submission Updates - 09/29/2026
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
FDAmedium relevance
Moderate corpus alignment
FDA document
View source
Register to make submissions to the MHRA
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

Korean Post-marketing Surveillance for Xeljanz XR
ClinicalTrials.govhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Virtual Reality (VR) -Directed Brain Gut Behavioral Treatment (BGBT) for Inflammatory Bowel Disease (IBD) Inpatients
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Randomized, Controlled, Exploratory Study on the Treatment of Dental Implants Using the AmbiJet System for Peri-implantitis and Peri-implant Mucositis
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Evaluation, Treatment and Monitoring of Patients With Known or Suspected Parasitic Infection
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Grants Approval for Glycerol Phenylbutyrate by Teva Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Approval for Pitolisant Hydrochloride by Novitium Pharma
Humanexa Signalsmedium relevance
Moderate corpus alignment

Elucidating the therapeutic mechanism of Gomisin G from Guomin Gecoction for psoriasis treatment through targeting the PI3K-AKT/JAK3-STAT3 pathway.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and drug survival after transitioning to IL-17 inhibitors in patients with psoriasis who did not respond to IL-23 inhibitors: analysis from the BIOREP registry.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Microneedle-based injection of Fungizone/Amphotericin B: an effective treatment for American cutaneous leishmaniasis in mice.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Investigation of the pharmacodynamic material basis and mechanism of Gexia Zhuyu Decoction in the treatment of primary dysmenorrhea with qi stagnation and blood stasis based on Chinmedomics.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Efficacy and safety of a novel 532-nm picosecond Nd:YAG laser for the treatment of freckles in Chinese patients: a randomized, split-face, multicenter, noninferiority trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Glenmark
Calcipotriene
psoriasis treatment market

Commercial impact

medium

Successful approval and market entry could allow Glenmark to capture market share from existing psoriasis treatments, impacting revenue streams for competitors.

Regulatory impact

medium

The acceptance of the ANDA indicates progress in the regulatory process, but the final approval decision remains pending, which could affect Glenmark's market strategy.

What to watch

Key milestones include the final approval decision and any subsequent market launch announcements.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.